Teladoc Health (NYSE:TDOC) Issues Q3 2026 Earnings Guidance

by · The Markets Daily

Teladoc Health (NYSE:TDOC – Get Free Report) updated its third quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of -0.300–0.200 for the period, compared to the consensus EPS estimate of -0.170. The company issued revenue guidance of $569.0 million-$609.0 million, compared to the consensus revenue estimate of $629.1 million. Teladoc Health also updated its FY 2026 guidance to -1.000–0.750 EPS.

Teladoc Health Stock Performance

TDOC traded down $0.15 on Wednesday, hitting $9.21. The company had a trading volume of 7,802,316 shares, compared to its average volume of 5,394,875. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -9.50 and a beta of 2.10. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.80 and a quick ratio of 2.72. The company’s fifty day moving average price is $8.16 and its 200 day moving average price is $6.54. Teladoc Health has a 1-year low of $4.40 and a 1-year high of $9.89.

Teladoc Health (NYSE:TDOC – Get Free Report) last released its earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Equities analysts predict that Teladoc Health will post -0.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Bank of America boosted their price target on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Weiss Ratings raised shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Canaccord Genuity Group upped their target price on shares of Teladoc Health from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Finally, Citigroup raised their price target on Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 5th. Five investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $7.57.

Get Our Latest Report on Teladoc Health

Insiders Place Their Bets

In other news, insider Adam C. Vandervoort sold 7,906 shares of Teladoc Health stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $60,322.78. Following the transaction, the insider owned 110,261 shares in the company, valued at $841,291.43. The trade was a 6.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $145,977.16. Following the completion of the transaction, the chief executive officer owned 389,894 shares of the company’s stock, valued at $2,974,891.22. This represents a 4.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 39,195 shares of company stock valued at $299,058 in the last three months. Insiders own 0.70% of the company’s stock.

Key Headlines Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

  • Positive Sentiment: Teladoc reported second-quarter adjusted EPS of $(0.21), better than the consensus estimate of $(0.24). Operating cash flow was $64.7 million, and the company ended the quarter with $774.3 million in cash and equivalents, supporting its liquidity position. Teladoc Health Reports Second Quarter 2026 Results
  • Positive Sentiment: Some valuation analysis continues to view TDOC as potentially undervalued after its substantial long-term decline, suggesting upside if the company can stabilize revenue and improve profitability. Teladoc Health Stock Still Looks Undervalued
  • Neutral Sentiment: Institutional positioning was mixed: 151 investors increased their holdings in the latest quarter, while 126 reduced positions. This indicates continued interest but no clear consensus among large investors.
  • Negative Sentiment: Second-quarter revenue fell 3.95% year over year to $606.9 million, missing the $627.7 million consensus estimate. Gross profit was $416.1 million, while the operating loss widened to $37.1 million, underscoring ongoing profitability challenges. Teladoc Health Q2 2026 Earnings
  • Negative Sentiment: Management’s outlook was below Wall Street expectations. Third-quarter revenue guidance of $569 million to $609 million trails the $629.1 million estimate, while projected EPS of $(0.30) to $(0.20) is worse than the $(0.17) consensus. Full-year revenue guidance of approximately $2.4 billion also falls short of the $2.5 billion forecast.
  • Negative Sentiment: Insiders reported 18 open-market sales and no purchases over the past six months. In addition, the median analyst price target of $7 is below recent trading levels, potentially limiting near-term upside.

Institutional Investors Weigh In On Teladoc Health

Several institutional investors have recently added to or reduced their stakes in TDOC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Teladoc Health by 2.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider’s stock valued at $1,542,000 after buying an additional 5,235 shares during the last quarter. NewEdge Advisors LLC lifted its stake in Teladoc Health by 1,278.7% in the first quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider’s stock valued at $90,000 after acquiring an additional 10,485 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Teladoc Health by 5.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider’s stock valued at $3,566,000 after acquiring an additional 24,124 shares during the period. Acadian Asset Management LLC acquired a new position in shares of Teladoc Health during the 1st quarter worth about $615,000. Finally, Envestnet Asset Management Inc. acquired a new position in shares of Teladoc Health during the 2nd quarter worth about $89,000. 76.82% of the stock is owned by institutional investors.

Teladoc Health Company Profile

(Get Free Report)

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.

Featured Stories